静脉血栓治疗药物拜瑞妥医保能报销吗？

(Rivaroxaban) is mainly used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). Rivaroxaban highly selectively and competitively inhibits free and bound factor Xa and prothrombin activity, prolonging activated partial thromboplastin time (PT) and prothrombin time (aPTT) in a dose-dependent manner.

The essential difference between Xarelto (rivaroxaban) and fondaparinux sodium/heparin is that it does not require the participation of antithrombin III and can directly antagonize free and bound factor During hip or knee replacement surgery, blood clots may form due to poor backflow of blood from leg veins to the heart. Rivaroxaban can help prevent the formation and further development of blood clots.

Xarelto (rivaroxaban) is a representative drug of FXa inhibitors. Xarelto received marketing approval in Canada and the European Union on September 15 and October 1, 2008 respectively. In June 2009, Xarelto (rivaroxaban) was officially launched in China. Can Xarelto, a venous thrombosis treatment drug, be reimbursed by medical insurance?

(Rivaroxaban) can be reimbursed by medical insurance and is a Class B drug. Patients can currently reimburse part of the cost through medical insurance when purchasing this drug. Drug categories include blood and hematopoietic organ drugs, anti-thrombotic drugs, anti-thrombotic drugs, and direct factor Xa inhibitors (XB>XB01>XB01A>XB01AF). Xarelto (rivaroxaban) medical insurance reimbursement conditions: limited to patients with non-valvular atrial fibrillation with poorly controlled warfarin therapy or high risk of bleeding; patients undergoing lower limb joint replacement surgery.

Recommended hot articles: /newsDetail/81460.html